AZITHRO-MAX 250 Tablet is an oral antibiotic preparation containing 250 mg of Azithromycin, a macrolide class antimicrobial agent with broad-spectrum bacteriostatic activity. It is designed to treat a wide variety of bacterial infections, especially those involving the respiratory tract, skin and soft tissues, genitourinary system, and ear, nose, and throat (ENT). As a semi-synthetic derivative of erythromycin, Azithromycin functions by binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis and suppressing bacterial proliferation. This mechanism allows AZITHRO-MAX 250 to effectively stop the growth of infection-causing pathogens and restore patient health efficiently.
AZITHRO-MAX 250 is commonly prescribed in the treatment of acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, sinusitis, pharyngitis, and tonsillitis. It is also an effective option in dermatological infections such as cellulitis, impetigo, folliculitis, and infected wounds. The medication is often utilized in urogenital infections including non-gonococcal urethritis and cervicitis caused by Chlamydia trachomatis. Due to its broad antibacterial coverage, AZITHRO-MAX 250 is suitable for both adults and pediatric patients when used in appropriate dosages.
One of the distinguishing features of AZITHRO-MAX 250 is its superior pharmacokinetic profile. It is rapidly absorbed from the gastrointestinal tract and achieves peak plasma concentrations within two to three hours post-administration. Azithromycin is characterized by extensive tissue distribution and high intracellular accumulation, particularly in phagocytic cells that transport the drug to infection sites. This targeted delivery ensures prolonged tissue concentrations even after plasma levels have declined, allowing for once-daily dosing and shorter treatment durations. This property is a significant advantage in enhancing patient adherence, especially in outpatient care.
A standard course of AZITHRO-MAX 250 may range from three to five days depending on the severity and type of infection. The reduced frequency of dosing and short duration of therapy compared to other antibiotics makes it a preferred option for patients and prescribers. Furthermore, Azithromycin has a long terminal half-life, typically around 68 hours, which supports its sustained activity and contributes to its post-antibiotic effect.
Description provided by bluepill express.
FIEO Registered
Export Ready
